Shape Memory Polymer Vascular Occlusion Device for the Treatment of Venous Insufficiency Phase II
Shape Memory Polymer Vascular Occlusion Device for the Treatment of Venous Insufficiency Phase II
批准号:
9255915
负责人:
Todd Landsman
金额:
$116.27万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-21 至 2018-08-31
关键词:
Abdominal PainAblationAccountingAcuteAddressAlloysAmericanAnimalsAreaBloodBlood Coagulation FactorBlood VesselsBlood flowBody RegionsBudgetsBurn injuryCathetersCicatrixCollaborationsCollagenConnective TissueDepositionDetergentsDevelopmentDevice DesignsDevicesDislocationsEffectivenessEndotheliumEnsureFatigueFibrinForeign-Body ReactionGoldGuidelinesHealedHealthcareHemorrhageHistologyHospitalizationHospitalsImageryIn VitroIndustryInfertilityInjection of therapeutic agentLaboratoriesLeadLeftLocationMechanicsMedical DeviceMemoryMethodsModalityMorphologyParticulatePatientsPeripheralPersistent painPhasePhysiciansPlaguePlatinumPolymersPolyurethanesPositioning AttributePredispositionProceduresPropertyRadiationRefluxRiskRuptureSafetySclerotherapyShapesSurfaceSystemTechnologyTensile StrengthTestingTexasTherapeuticTherapeutic EmbolizationThromboembolismThrombusTimeTissuesToxic effectTreatment CostUlcerUltrasonographyUnited StatesUniversitiesVaricosityVeinsVenousVenous InsufficiencyWalkingWorkbiomaterial compatibilitychronic abdominal paincostexperiencefollow-uphealingimplantationin vivomigrationminimal riskneurovascularpre-clinicalpreventprototypereduce symptomsrestorationskillsstandard caretissue support frame
中文摘要
摘要
静脉功能不全(VI)是每年超过500,000例住院的原因,
在美国,每年的医疗费用超过10亿美元,占
约占整个医疗保健预算的2%。VI发生时,静脉内的瓣膜
身体虚弱,不能再防止回流和血液淤积。结果,静脉扩张
如果不及时治疗,会导致持续性腹痛、不孕,甚至溃疡形成。
为了减轻VI的症状,医生的目标是永久排除病变血管
从系统性流动。目前治疗的金标准是植入铂
栓塞线圈结合清洁剂注射,称为硬化疗法,
灼伤血管内皮并导致静脉内的瘢痕形成。但截至
15%的患者经历再通,或通过先前的血管恢复血流。
治疗的船只。这通常需要患者接受第二次甚至第三次治疗,
永久性地阻塞静脉治疗还可能需要植入多达16个线圈,
这造成了治疗设施的高昂的设备成本,并增加了辐射暴露
为了病人
拟议的项目概述了形状记忆聚合物的持续发展
(SMP)泡沫外周栓塞器械(PED)治疗VI相关并发症。的
PED将提供快速、完全的静脉闭塞,器械风险最小
脱位、血管破裂和周围组织损伤。可治疗静脉的领域
与VI也将通过PED的材料特性和容易地
输送至迂曲血管。
将进行台架器械验证研究,以确保申报器械
具有足够的机械强度,需要最小的力来推进通过
导管,SMP泡沫牢固地连接到PED以防止血栓栓塞。的
PED的生物相容性也将通过ISO 10993研究进行广泛评价
通常在这类设备上执行。最后,PED将交付给十二个
临床前动物,并分析了输送和导航的便利性、器械移位、
30天和90天随访时的闭塞、再通以及局部和全身毒性。在
这项工作的最终结果是,向FDA提交510(k)许可所需的所有研究
将完成。
英文摘要
ABSTRACT
Venous insufficiency (VI) is the cause of more than 500,000 annual hospitalizations in
the U.S. and accounts for more than $1 billion in annual healthcare expenses, accounting for
approximately 2% of the entire healthcare budget. VI occurs when the valves within veins are
weakened and can no longer prevent backflow and blood pooling. As a result, the vein dilates
and if left untreated can cause persistent abdominal pain, infertility, and even ulcer formation.
To alleviate the symptoms of VI, physicians aim to permanently exclude the diseased vessel
from systemic flow. The current gold standard of treatment is the implantation of platinum
embolic coils combined with a detergent injection, known as sclerotherapy, which chemically
burns the endothelium of the vessel and causes scar formation within the vein. However, up to
15% of patients experience recanalization, or the restoration of blood flow through a previously
treated vessel. This often requires the patient to undergo a second, or even third treatment, to
permanently occlude the vein. Treatments can also require the implantation of up to 16 coils,
which creates prohibitive device costs for treatment facilities, and increased radiation exposure
for the patient.
The proposed project outlines the continued development of a shape memory polymer
(SMP) foam peripheral embolization device (PED) to treat complications associated with VI. The
PED will provide rapid, complete occlusion of the refluxing veins with minimal risk of device
dislocation, vessel rupture, and damage to surrounding tissues. The realm of treatable veins
with VI will also be extended by the material properties of the PED and the ability to be easily
delivered to tortuous vessels.
Benchtop device verification studies will be performed to ensure the proposed device
has adequate mechanical strength, requires minimal force for advancement through the
catheter, and the SMP foam is securely attached to the PED to prevent thromboembolism. The
biocompatibility of the PED will also be extensively evaluated through ISO 10993 studies
typically performed on this class of devices. Finally, the PED will be delivered to twelve
preclinical animals and analyzed for ease of delivery and navigation, device migration, time to
occlusion, recanalization at 30 and 90-day follow up, and local and system toxicity. At the
culmination of this work, all studies necessary for submission to the FDA for 510(k) clearance
will be completed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Shape Memory Polymer Foam Vascular Occlusion Device for the Treatment of Chronic Venous Insufficiency
-
批准号:8979042
-
项目类别:
-
资助金额:$19.96万
-
财政年份:2015
-
负责人:Todd Landsman
-
依托单位:
Shape Memory Polymer Foam Vascular Occlusion Device for the Treatment of Chronic Venous Insufficiency
-
批准号:9134385
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2015
-
负责人:Todd Landsman
-
依托单位:
海外基金